Earnings Feed
Start Free
Home/Filings/4/0001225208-11-011387
4//SEC Filing

GENZYME CORP 4

Accession 0001225208-11-011387

CIK 0000732485operating
View on SEC.govCompany Profile

Filed

Apr 5, 8:00 PM ET

Accepted

Apr 6, 2:03 PM ET

Size

39.8 KB

Accession

0001225208-11-011387

Insider Transaction Report

Form 4
Period: 2011-04-04
GENZYME CORPGENZ
COONEY CHARLES L
Director
Transactions
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.66/sh−7,500$439,950→ 0 total
    Exercise: $58.66From: 2010-05-21Exp: 2019-05-21→ Genzyme common stock (GENZ) (7,500 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$62.98/sh−15,000$944,700→ 0 total
    Exercise: $62.98From: 2006-05-26Exp: 2015-05-26→ Genzyme common stock (GENZ) (15,000 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+2,375→ 15,491.389 total
  • Disposition to Issuer

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−2,375$175,750→ 13,266.206 total
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−600$44,400→ 0 total(indirect: By Children)
  • Exercise/Conversion

    Restricted Stock Units

    2011-04-04−2,375→ 0 total
    Exercise: $0.00→ Genzyme common stock (GENZ) (2,375 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$62.16/sh−15,000$932,400→ 0 total
    Exercise: $62.16From: 2008-05-24Exp: 2017-05-24→ Genzyme common stock (GENZ) (15,000 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+149.817→ 15,641.206 total
  • Disposition to Issuer

    Genzyme common stock (GENZ)

    2011-04-04$76.01/sh−3,977.206$302,307→ 9,289 total
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−8,387$620,638→ 902 total
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−1,882$139,268→ 0 total(indirect: By Son)
  • Disposition from Tender

    Genzyme common stock (GENZ)

    2011-04-04$74.00/sh−240$17,760→ 0 total(indirect: By Spouse)
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−149.817→ 0 total
    From: 2002-09-30Exp: 2026-12-31→ Genzyme common stock (GENZ) (149.817 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$58.50/sh−15,000$877,500→ 0 total
    Exercise: $58.50From: 2007-05-25Exp: 2016-05-26→ Genzyme common stock (GENZ) (15,000 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$41.51/sh−1,010$41,925→ 0 total
    Exercise: $41.51From: 2003-05-30Exp: 2012-05-30→ Genzyme common stock (GENZ) (1,010 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$53.47/sh−2,000$106,940→ 0 total
    Exercise: $53.47From: 2002-05-31Exp: 2011-05-31→ Genzyme common stock (GENZ) (2,000 underlying)
  • Exercise/Conversion

    Genzyme common stock (GENZ)

    2011-04-04+3,827.389→ 13,116.389 total
  • Exercise/Conversion

    Phantom Stock

    2011-04-04−3,827.389→ 0 total
    From: 2002-06-30Exp: 2026-12-31→ Genzyme common stock (GENZ) (3,827.389 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$51.52/sh−7,125$367,080→ 0 total
    Exercise: $51.52Exp: 2020-06-16→ Genzyme common stock (GENZ) (7,125 underlying)
  • Disposition to Issuer

    Stock Option (right to buy)

    2011-04-04$68.48/sh−7,500$513,600→ 0 total
    Exercise: $68.48From: 2009-05-22Exp: 2018-05-22→ Genzyme common stock (GENZ) (7,500 underlying)
Footnotes (3)
  • [F1]The phantom stock acquired under the Genzyme Directors? Deferred Compensation Plan was cancelled at the completion of the sanofi-aventis tender offer and converted into the right to receive a cash payment based on the closing price of Genzyme common stock on the last day it traded. Phantom stock was credited to the Reporting Person?s stock account under the deferred compensation at the end of each fiscal quarter from 4/1/2002 through 9/30/2002, pursuant to the Reporting Person?s plan election and the terms of the plan.
  • [F2]The vested restricted stock units were scheduled to vest on the date of the 2011 annual meeting of shareholders.
  • [F3]This option, which provided for vesting at the next annual meeting of shareholders, was cancelled upon the consummation of the sanofi-aventis tender offer in exchange for a payment representing (A) an amount of cash equal to the excess of $74.00 over the exercise price of the option, multiplied by the total number of shares subject to such options, and (B) one contingent value right (CVR) per cancelled option.

Documents

1 file

Issuer

GENZYME CORP

CIK 0000732485

→
Entity typeoperating
IncorporatedMA

Related Parties

1
  • filerCIK 0000732485

Filing Metadata

Form type
4
Filed
Apr 5, 8:00 PM ET
Accepted
Apr 6, 2:03 PM ET
Size
39.8 KB
View on SEC.gov